KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Receivables (2016 - 2025)

Historic Receivables for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Q3 2025 value amounting to $764.4 million.

  • Jazz Pharmaceuticals' Receivables rose 562.78% to $764.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $764.4 million, marking a year-over-year increase of 562.78%. This contributed to the annual value of $716.8 million for FY2024, which is 155.44% up from last year.
  • According to the latest figures from Q3 2025, Jazz Pharmaceuticals' Receivables is $764.4 million, which was up 562.78% from $714.0 million recorded in Q2 2025.
  • Over the past 5 years, Jazz Pharmaceuticals' Receivables peaked at $764.4 million during Q3 2025, and registered a low of $414.0 million during Q1 2021.
  • Moreover, its 5-year median value for Receivables was $627.8 million (2023), whereas its average is $628.8 million.
  • As far as peak fluctuations go, Jazz Pharmaceuticals' Receivables skyrocketed by 4397.02% in 2021, and later plummeted by 765.14% in 2025.
  • Quarter analysis of 5 years shows Jazz Pharmaceuticals' Receivables stood at $563.4 million in 2021, then rose by 15.64% to $651.5 million in 2022, then rose by 8.33% to $705.8 million in 2023, then rose by 1.55% to $716.8 million in 2024, then grew by 6.64% to $764.4 million in 2025.
  • Its last three reported values are $764.4 million in Q3 2025, $714.0 million for Q2 2025, and $653.0 million during Q1 2025.